Seher Şener, Ezgi Deniz Batu, Özge Başaran, Zeynep Balık, Emil Aliyev, Yağmur Bayındır, Veysel Çam, Yelda Bilginer, Seza Özen
{"title":"系统性青少年特发性关节炎的治疗：常规治疗与生物制剂。","authors":"Seher Şener, Ezgi Deniz Batu, Özge Başaran, Zeynep Balık, Emil Aliyev, Yağmur Bayındır, Veysel Çam, Yelda Bilginer, Seza Özen","doi":"10.24953/turkjpediatr.2025.5482","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>We aimed to identify and compare systemic juvenile idiopathic arthritis (sJIA) patients receiving treatment with either glucocorticoids and/or conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) or biologic drugs.</p><p><strong>Methods: </strong>This was a retrospective cross-sectional study. sJIA patients (n=138) were categorized into two groups: Group A (n=51) consisted of individuals who received only glucocorticoids and/or csDMARDs, while Group B (n=87) included those who received at least one biologic drug.</p><p><strong>Results: </strong>Group B patients exhibited a higher prevalence of macrophage activation syndrome (MAS) (p=0.001) at presentation. C-reactive protein (CRP) levels and systemic Juvenile Arthritis Disease Activity Scores (sJADAS) at diagnosis were significantly higher in Group B (p.</p>","PeriodicalId":101314,"journal":{"name":"The Turkish journal of pediatrics","volume":"67 1","pages":"61-68"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment of systemic juvenile idiopathic arthritis: conventional treatment versus biologics.\",\"authors\":\"Seher Şener, Ezgi Deniz Batu, Özge Başaran, Zeynep Balık, Emil Aliyev, Yağmur Bayındır, Veysel Çam, Yelda Bilginer, Seza Özen\",\"doi\":\"10.24953/turkjpediatr.2025.5482\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>We aimed to identify and compare systemic juvenile idiopathic arthritis (sJIA) patients receiving treatment with either glucocorticoids and/or conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) or biologic drugs.</p><p><strong>Methods: </strong>This was a retrospective cross-sectional study. sJIA patients (n=138) were categorized into two groups: Group A (n=51) consisted of individuals who received only glucocorticoids and/or csDMARDs, while Group B (n=87) included those who received at least one biologic drug.</p><p><strong>Results: </strong>Group B patients exhibited a higher prevalence of macrophage activation syndrome (MAS) (p=0.001) at presentation. C-reactive protein (CRP) levels and systemic Juvenile Arthritis Disease Activity Scores (sJADAS) at diagnosis were significantly higher in Group B (p.</p>\",\"PeriodicalId\":101314,\"journal\":{\"name\":\"The Turkish journal of pediatrics\",\"volume\":\"67 1\",\"pages\":\"61-68\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-02-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Turkish journal of pediatrics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24953/turkjpediatr.2025.5482\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Turkish journal of pediatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24953/turkjpediatr.2025.5482","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Treatment of systemic juvenile idiopathic arthritis: conventional treatment versus biologics.
Objective: We aimed to identify and compare systemic juvenile idiopathic arthritis (sJIA) patients receiving treatment with either glucocorticoids and/or conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) or biologic drugs.
Methods: This was a retrospective cross-sectional study. sJIA patients (n=138) were categorized into two groups: Group A (n=51) consisted of individuals who received only glucocorticoids and/or csDMARDs, while Group B (n=87) included those who received at least one biologic drug.
Results: Group B patients exhibited a higher prevalence of macrophage activation syndrome (MAS) (p=0.001) at presentation. C-reactive protein (CRP) levels and systemic Juvenile Arthritis Disease Activity Scores (sJADAS) at diagnosis were significantly higher in Group B (p.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
